A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients

Clinical trial NCT04847583 · TERMINATED

Trial details

NCT number: NCT04847583
Sponsor: Qurient Co., Ltd.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

COVID-19 Virus Infection

Start date: 2021-07-29
Primary completion: 2022-02-11
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.